2013 NLA Scientific Sessions Highlights
Promise and Pitfalls of Lifetime Risk Assessment for CVD
Donald Lloyd-Jones, MD
Donald Lloyd-Jones, MD presented there is no Lifetime Risk versus Ten Year Risk but rather Lifetime Risk is an addition to Ten Year Risk. Dr. Lloyd-Jones concludes that Lifetime Risk helps with "high-risk strategy" it can help identify younger individuals with low short-term risk but with a high lifetime risk.
Tags:
NLA HDL Consensus Statement
Peter P. Toth, MD, PhD, FNLA
Peter P. Toth, MD, PhD, presented the National Lipid Association's HDL Consensus Statement that is set to be published in the Journal of Clinical Lipidology in the November/December issue.
Tags:
DHA AND THE BRAIN: Is it an Essential Nutrient?
Susan E. Carlson, PhD
Susan Carlson, PhD, presented that while DHA is essential for optimal brain function, much more research is needed to be able to determine if it is an essential nutrient for persons consuming α-linolenic acid.
Tags:
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
Don P. Wilson, MD
Don P. Wilson, MD, presented that over the past three decades it has become evident that atherosclerosis has its origins in childhood. Children and adolescents with genetic and/or acquired CVD risk factors can be easily identified. When present at a young age, these risk factors track into adulthood and have been associated with moderate-to-high risk of future cardiovascular disease.
Tags:
HPS2-THRIVE
Jane Armitage, FRCP, FFPH
Jane Armitage, FRCP, FFPH, presented the HPS-2 THRIVE clinical trial. During her talk, Professor Armitage conveys that the trial found no significant benefit of ER niacin/laropiprant on the primary outcome of major vascular events when added to optimal statin-based LDL-lowering therapy. In addition, results from HPS-2 THRIVE showed significant excesses of serious adverse events (SAEs) due to known and unrecognized side-effects of niacin.
Tags:
